University of Roma La Sapienza

uniroma1.it

Total trials

386

Active

40

Phase 3

22

Total enrollment

100,045

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 8 of 8 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
PDD-TURBT with hexaminolevulinate1
Oral iron supplementation1
IV iron administration1
Magnesium-PEA-HMW Hyaluronic Acid-Vitamin B6-Vitamin D + Vaginal Progesterone1
Pentabiocel1
Antiplatelet Agents1
Somatostatin analog; chemotherapy1
CHX 0.12%1

Next readouts

  • 2025-03
  • 2025-07-31
  • 2025-09-14
  • 2025-12-31
  • 2027-04-01
  • 2028-07-01
  • 2028-12

Top conditions

  • Coronary Artery Disease25
  • Obesity17
  • Septic Shock8
  • Bariatric Surgery Candidate6
  • Wound Heal5
  • Pain5
  • HIV4
  • Arterial Hypertension4

Frequently asked questions about University of Roma La Sapienza

How many clinical trials does University of Roma La Sapienza have on ClinicalTrials.gov?
University of Roma La Sapienza is listed as the lead sponsor on 386 clinical trials in ClinicalTrials.gov, 40 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Roma La Sapienza's trials are in Phase 3?
22 of University of Roma La Sapienza's trials are in Phase 3, spread across 8 active drug programs.
What therapeutic areas does University of Roma La Sapienza focus on?
University of Roma La Sapienza's most-studied conditions on ClinicalTrials.gov are Coronary Artery Disease, Obesity, Septic Shock, Bariatric Surgery Candidate, Wound Heal.
When are University of Roma La Sapienza's next clinical trial readouts?
University of Roma La Sapienza has 7 upcoming primary-completion readouts tracked here; the soonest is “Clinical Efficacy of a Chlorhexidine-based Mouth-rinse Containing Citrus Aurantium Amara”, expected around 2025-03.